This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
A Turning Point in MASH
A billion-dollar acquisition, breakthrough clinical data, and a shifting scientific paradigm are pushing MASH out of the shadows and into a new era of metabolic medicine.
